WIPOProtect this trademark from copycats!
With our trademark monitoring alerts, you are automatically notified by email about copycats and free riders.
The International trademark BICYCLE RADIONUCLIDE THERAPY was filed as Word mark on 02/25/2022 at the World Intellectual Property Organization.
| Trademark form | Word mark |
| File reference | 1662119 |
| Register number | UK00003698774 |
| Countries | 
|
| Base trademark |
No. UK00003698774,
January 7, 2022
|
| Application date | February 25, 2022 |
| Expiration date | February 25, 2032 |
Trademark owner
Blocks A & B Portway Building,
Granta Park
GB
Granta Park
GB
Trademark representatives
Lacon London,
84 Theobalds Road,
GB
goods and services
05
Pharmaceuticals; pharmaceutical preparations; pharmaceutical
products; pharmaceutical products and preparations for use
in relation to oncology; pharmaceutical products and
preparations for use in relation to ophthalmology;
pharmaceutical products and preparations for use in relation
to neurology; anti-infective pharmaceutical products and
preparations; pharmaceutical products and preparations for
the treatment and/or prevention of respiratory disease;
pharmaceutical products and preparations for the treatment
and/or prevention of cardiovascular disease; pharmaceutical
products and preparations for the treatment and/or
prevention of metabolic disease; pharmaceutical products and
preparations for the treatment and/or prevention of viral
infections; pharmaceutical products and preparations for use
in diagnostics and imaging; pharmaceutical products and
preparations for the treatment and/or prevention of renal
disease; pharmaceutical products and preparations for the
treatment and/or prevention of gastrointestinal disease;
pharmaceutical products and preparations for the treatment
and/or prevention of muscular skeletal disease
42
Scientific and technological services and research and
design relating thereto; industrial analysis and research
services; pharmaceutical research and development services;
medical research and development services; pharmaceutical
testing and clinical trials; clinical trials; research and
development in the field of oncology; research and
development in the field of ophthalmology; research and
development in the field of neurology; research and
development in the field of anti-infective pharmaceuticals;
research and development in the field of respiratory
disease; research and development in the field of
cardiovascular disease; research and development in the
field of metabolic disease; research and development in the
field of antiviral drugs; research and development in the
field of diagnostics and imaging; research and development
in the field of renal disease; research and development in
the field of gastrointestinal disease; research and
development in the field of muscular skeletal disease;
information consultancy and advisory services relating to
the aforesaid
44
Medical services; medical testing; healthcare services;
pharmaceutical services; medical consulting services;
advisory services relating to pharmaceuticals; consultancy
and information services relating to pharmaceuticals;
medical services in the field of oncology; medical services
in the field of ophthalmology; medical services in the field
of neurology; medical services in the field of
anti-infectives; medical services in connection with
respiratory disease; medical services in connection with
cardiovascular disease; medical services in connection with
metabolic disease; medical services in connection with the
treatment and/or prevention of viral infections; medical
services in connection with diagnostics and imaging; medical
services in connection with renal disease; medical services
in connection with gastrointestinal disease; medical
services in connection with muscular skeletal disease;
pharmaceutical services in the field of oncology;
pharmaceutical services in the field of ophthalmology;
pharmaceutical services in the field of neurology;
pharmaceutical services in the field of anti-infectives;
pharmaceutical services in connection with respiratory
disease; pharmaceutical services in connection with
cardiovascular disease; pharmaceutical services in
connection with metabolic disease; pharmaceutical services
in connection with the treatment and/or prevention of viral
infections; pharmaceutical services in connection with
diagnostics and imaging; pharmaceutical services in
connection with renal disease; pharmaceutical services in
connection with gastrointestinal disease; pharmaceutical
services in connection with muscular skeletal disease;
information, consultancy and advisory services relating to
the aforesaid
Trademark history
| Date | Document number | Area | Entry |
|---|---|---|---|
| February 23, 2023 | 2023/8 Gaz | JP | Rejection |
| October 28, 2022 | 2022/44 Gaz | US | Rejection |
| October 6, 2022 | 2022/40 Gaz | EM | Rejection |
| February 25, 2022 | 2022/18 Gaz | GB | Registration |
ID: 141662119